IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 19.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,463 shares of the medical research company’s stock after purchasing an additional 407 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in IQVIA were worth $584,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in IQVIA in the 2nd quarter valued at approximately $27,000. Capital Performance Advisors LLP purchased a new stake in IQVIA in the third quarter valued at approximately $27,000. Park Place Capital Corp acquired a new stake in shares of IQVIA in the third quarter valued at $28,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA in the second quarter valued at $29,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on IQV. Barclays lowered their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday. Truist Financial reduced their target price on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, BTIG Research reduced their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $256.50.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 6.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is owned by company insiders.

IQVIA Stock Up 2.1 %

IQV stock opened at $201.82 on Friday. The stock has a market cap of $36.63 billion, a P/E ratio of 26.49, a PEG ratio of 1.97 and a beta of 1.51. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company’s 50 day moving average is $222.67 and its two-hundred day moving average is $227.18.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.